NextGen Biomed (XTAE:NXGN) EBIT per Share : ₪-1.24 (TTM As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed EBIT per Share?

NextGen Biomed's EBIT per Share for the six months ended in Jun. 2023 was ₪-0.28. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was ₪-1.24.

During the past 3 years, the average EBIT per Share Growth Rate was -24.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was -11.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for NextGen Biomed's EBIT per Share or its related term are showing as below:

XTAE:NXGN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -24.5 Med: 15.9 Max: 65
Current: -24.5

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of NextGen Biomed was 65.00% per year. The lowest was -24.50% per year. And the median was 15.90% per year.

XTAE:NXGN's 3-Year EBIT Growth Rate is ranked worse than
80.69% of 725 companies
in the Medical Devices & Instruments industry
Industry Median: 5.7 vs XTAE:NXGN: -24.50

NextGen Biomed's EBIT for the six months ended in Jun. 2023 was ₪-2.04 Mil.

NextGen Biomed EBIT per Share Historical Data

The historical data trend for NextGen Biomed's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed EBIT per Share Chart

NextGen Biomed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-0.25

-0.24

-0.39

-1.18

NextGen Biomed Semi-Annual Data
	Dec13	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT per Share	Get a 7-Day Free Trial													-0.20	-0.18	-1.29	-0.96	-0.28

NextGen Biomed EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

NextGen Biomed's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.516	/	7.225
=	-1.18

NextGen Biomed's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.036	/	7.263
=	-0.28

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪-1.24

NextGen Biomed (XTAE:NXGN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

NextGen Biomed EBIT per Share Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NextGen Biomed (XTAE:NXGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101

Website

http://www.nextgen-biomed.com

NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.